In this study, all five tumors showed moderate-to-strong ER immunoreactivity in ≥50% tumor cells, and four tumors demonstrated moderate-to-strong PR immunoreactivity in ≥60% tumor cells. The gene discussed is ESR1; the disease is neoplasm.